Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 10, 2012

View Archived Issues

New auristatin derivatives for cancer prepared at Bayer Schering Pharma

Preclinical study identifies new Wnt signaling inhibitors that regulate cardiogenesis

Novel approach leads to discovery of NME that prevents tumor invasion

Silence Therapeutics and miRagen to collaborate on microRNA-based therapeutics

KAI Pharmaceuticals begins recruitment in second phase II study of KAI-4169

Ongoing phase I/II trial assesses combinations of letrozole with SAR-245408 and SAR-245409

Phase I/II data presented on SAR-245408-based combination regimens in metastatic breast cancer

New Evestra progesterone receptor inhibitor shows potential as breast cancer therapy

AstraZeneca patents new protein kinase inhibitors

Novel estrogen receptor-alpha modulators prepared by Aragon Pharmaceuticals

AstraZeneca and Pulmagen Therapeutics patent novel compounds for respiratory disorders

Clinical study of intranasally administered HIV vaccine fully enrolled

Scientists at Merck & Co. prepare new PRCP inhibitors

MDA provides financial support for preclinical work on TVN-102

New MAP kinase p38 inhibitors synthesized

Ista Pharmaceuticals begins phase II trial of combination nasal spray for seasonal allergic rhinitis

MHRA accepts Shire's MAA for once-daily ADHD therapy for review

Novel serine/threonine-protein kinase PAK inhibitors designed

Pfizer begins phase I study of PF-05280602

GSK and Theravance report data from phase III Relovair studies

Civitas Therapeutics reports results from phase I CVT-301 trial

Phase II trial of diabetes vaccine reaches full enrollment

Novavax provides update on joint venture in India

Astellas and Theravance terminate license agreement

Alnylam files ALN-TTR02 CTA with MHRA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 30, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...